Compare Summit Therapeutics Inc (SMMT) vs Workday Inc (WDAY) Price & Performance

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Workday (WDAY) trades at $174.53, down 5.24% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust revenue growth, reaching $8.45B in 2025 with consistent earnings beats. Recent partnerships and AI product launches, including Workday Learning and FedRAMP authorization, highlight strategic expansion. Analyst consensus remains positive with 55.6% buy ratings despite a recent downgrade from Morgan Stanley on July 21, 2026.

WDAY's outlook is supported by solid fundamentals and AI-driven growth initiatives, though elevated valuation metrics (P/E 56.47) and institutional selling pose risks. The stock faces near-term pressure from overbought technical indicators but maintains long-term potential through enterprise software demand and market leadership in HR/finance solutions.